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and Glenn M. LaMuraglia, MD, Boston, Mass
Background: Percutaneous endovascular therapy is becoming a primary option for managing infrainguinal occlusive
disease. This study examined the results of femoropopliteal percutaneous transluminal angioplasty (PTA) with interme-
diate (mean, 24 months) follow-up in a contemporary series of patients presenting with critical limb ischemia or
claudication.
Methods: Femoropopliteal PTA was performed on 238 consecutive limbs (208 patients) from January 2002 to July 2004.
Study end points, including primary patency, assisted patency, and limb salvage (Society of Vascular Surgery reporting
standards), were assessed by Kaplan-Meier life-table analysis, and factors predictive of hemodynamic or clinical failure, or
both, were evaluated by univariate and multivariate methods.
Results: Clinical and demographic features included a mean age, 72 years; male (62%); critical limb ischemia (46%);
diabetes mellitus (49%); and renal insufficiency (creatinine> 1.5 mg/dL) (29%). Lesions were classified as TransAtlantic
Inter-Society Consensus (TASC) A (11%), B (43%), C (41%), and D (5%). PTA was confined to the femoropopliteal
segment in 77 patients (33%), and 161 (67%) underwent concurrent interventions in other anatomic locations.
Femoropopliteal interventions included angioplasty only in 183 (78%), and the remaining 53 (22%) received at least one
stent. Technical success was achieved in 97% of patients, with no deaths and a major morbidity rate of 3%. The 36-month
actuarial primary patency was 54.3%, and assisted patency was 92.6% (37 peripheral reinterventions), resulting in a limb
preservation rate of 95.4% in all patients regardless of clinical presentation. Interval conversion to bypass surgery occurred
in 19 patients (8%). Comparison between critical limb ischemia and claudication revealed a primary patency of 40.8% vs
64.8%, assisted patency of 93.8% vs 92.6%, and limb salvage of 89.7% vs 100%, respectively. Negative predictors of
primary patency determined by multivariate analysis included history of congestive heart failure (P  .02) and TASC
C/D (P  .02). However, further evaluation of TASC C/D vs A/B revealed an assisted patency of 89.7% vs 94.3% (P 
.37) and limb salvage of 94.3% vs 96.4% (P  .58).
Conclusions: Femoropopliteal PTA can be performed with a low perioperative morbidity and mortality. Intermediate
primary patency is directly related to TASC classification. Although secondary intervention is often necessary to maintain
patency in TASC C/D lesions, these data suggest that it would be appropriate to use PTA as initial therapy for chronic
femoropopliteal occlusive disease regardless of clinical classification at presentation or TASC category of lesion severity.
(J Vasc Surg 2006;44:762-9.)Chronic lower extremity ischemia secondary to athero-
sclerotic disease accounts for more than 400,000 hospitaliza-
tions in the United States each year and has been associated
with a 20% annual mortality, mostly from cardiovascular
events.1,2 For patients with critical limb ischemia (CLI),
surgical bypass grafting has been the gold standard, with
5-year limb salvage rates 80% in patients presenting with
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762a nonhealing ulcer or rest pain.3,4 Conversely, the mainstay
of treatment for intermittent claudication has been medi-
cal, with aggressive risk factor control, exercise training,
and pharmacologic management; surgical bypass being re-
served for patients who fail this conservative approach.5,6
Infrainguinal bypass can be performed safely with a low
perioperative mortality; however, because of pre-existing co-
morbid conditions, local and systemic postoperative morbid-
ity approaches 30% in this patient population.7-9 Further-
more, patients often experience an extended recovery interval
after infrainguinal bypass and 50% report a return to their
preoperative functional status by 6 months.10
Percutaneous transluminal angioplasty with or without
stenting (PTA/stent) for chronic lower extremity ischemia
has been well established as first-line therapy for aortoiliac
occlusive disease, with a low morbidity and excellent long-
term patency. Despite similar low complication rates after
infrainguinal PTA/stent, primary patency rates inferior to
surgical bypass have fueled the argument that this modality
should be reserved for patients who are at high surgical risk
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development of small-diameter catheter platforms (0.014-
inch and 0.018-inch), which have improved the technical
methodology, and the introduction of flexible nitinol
stents, which has created a perception of improved early
patency, has promulgated the use of PTA/stent as the
initial option for infrainguinal reconstruction, despite a lack
of data to support this practice.14-17
The purpose of this study was to evaluate the mid-term
results of endovascular treatment of femoropopliteal arte-
rial disease in a contemporary series of patients with chronic
lower extremity ischemia.
METHODS
Patients. All patients with femoropopliteal occlusive
disease who were managed with PTA/stent between Jan-
uary 2002 and July 2004 were identified. During the study
interval, 208 patients underwent PTA/stent for native
femoropopliteal arterial lesions, with 238 limbs treated.
The decision to use PTA/stent as first line therapy was
based on the clinical examination, anatomic evaluation, and
judgment of the attending surgeon involved. Individual
limbs were counted separately so that patients undergoing
staged, bilateral procedures were recorded and evaluated as
two entries. The Institutional Review Board of the Massa-
chusetts General Hospital approved the clinical protocol.
Patients who presented with acute critical limb isch-
emia requiring emergent revascularization or a functionally
unsalvageable limb were excluded from evaluation. Also
excluded were patients who underwent PTA/stent of
threatened bypass grafts (vein or prosthetic) or received
mechanical thrombectomy, atherectomy, or thrombolysis.
Demographic, preoperative, perioperative, and postoper-
ative data, including clinical presentation (Rutherford classifi-
cation),18 lesion anatomy according to the TransAtlantic In-
ter-Society Consensus (TASC) classification,19 and follow-up
ankle-brachial indices (ABI) or pulse volume recordings
(PVR), or both, were collected for each patient. Renal
insufficiency was defined as a serum creatinine level of1.5
mg/dL, and patients were considered to have a history of
heart disease even if they had previously been revascularized
with coronary artery angioplasty or bypass grafting. The
TASC classification for femoropopliteal occlusive disease
includes:
● TASC A: A single stenosis 3 cm long, not at the
origin of the superficial femoral or distal popliteal
artery.
● TASC B: A single stenosis or occlusion 3 to 5 cm long
not involving the distal popliteal, or multiple stenoses
or occlusions, each 3 cm long.
● TASC C: A single stenosis or occlusion 5cm, or
multiple lesions each 3 to 5 cm long.
● TASC D: Complete common femoral or superficial
femoral artery occlusions, or complete popliteal and
proximal trifurcation occlusions.
PTA/stent procedure. All femoropopliteal PTA/
stent procedures were performed in our fixed-imaging op-erating room suite or cardiac catheterization lab by vascular
surgeons who satisfied Society of Vascular Surgery criteria
for performance of endovascular procedures.
Patients with preoperative renal insufficiency were rou-
tinely given oral acetylcysteine before interventions and
gadolinium-iodinated contrast mixtures were used in the
severely azotemic patients. Selective angiography was per-
formed under local anesthesia through a contralateral, ret-
rograde, or ipsilateral antegrade common femoral artery
approach using 5F or 6F sheaths. No popliteal punctures
were used for vascular access.
Lesions were crossed with platinum-tipped (0.018-
inch, 0.014-inch) or hydrophilic wires (0.035-inch, 0.018-
inch, 0.014-inch), and balloon angioplasty was performed
under systemic anticoagulation. Subintimal angioplasty was
not routinely used to traverse occluded lesions. Balloon
catheter diameter was chosen to match the nondiseased
artery adjacent to the lesion. Indiscriminate use of long
angioplasty balloons was avoided to prevent unnecessary
arterial injury or dissection. Balloon inflation pressures
ranged from 4 to 12 atm and were held for at least
60 seconds. Nitinol self-expanding stents were selectively
used for flow-limiting dissections or when angioplasty
alone did not produce a satisfactory result. Sheaths were
removed under manual compression, and closure devices
were rarely used.
Lesion anatomy was recorded by the operator for fur-
ther analysis, and lesions were then classified according to
the TASC criteria.19 All patients were given a 300-mg
loading dose of clopidogrel after the procedure and were
maintained on 75 mg/d for 6 to 12 weeks. Patients also
received 325mg of aspirin on the day of the procedure, and
this was continued indefinitely.
Postprocedure follow-up. Patients were routinely
evaluated at 6 weeks in the outpatient setting with clinical
examination and lower extremity noninvasive studies, which
included both ABI and PVR, and then in 6-month intervals
thereafter. Patients with noncompressible vessels were most
commonly monitored with PVR. Patency was determined
according to the Rutherford guidelines,18 and patients who
had absent distal pulses, a return of symptoms, or a change
in ABI/PVR underwent further imaging. Follow-up also
involved a review of all outpatient clinic visits and hospital
admissions documented in our system-wide electronic
medical record.
Definitions and endpoints. PTA/stent was consid-
ered angiographically successful when all technically acces-
sible lesions were treated with a 20% residual stenosis.
Hemodynamic success was defined as an ABI increase of
0.10 or improvement in plethysmographic tracing by
5 mm for patients with noncompressible vessels. Clinical
success was defined as an improvement of at least one
clinical category, with demonstrable hemodynamic success
for patients in categories 1 to 4. Patients with tissue loss
(categories 5 and 6) required an improvement to at least
claudication and healing of their ulcers, with confirmed
improved hemodynamics as defined by published reporting
standards.18
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toms in the face of worsening ABIs or dampened PVRs due
to recurrent femoropopliteal disease. Assisted patency was
achieved through secondary PTA/stent involving the fem-
oropopliteal segment regardless of whether the recurrent
lesion was a stenosis, occlusion, or a new lesion in the same
anatomic segment.
Patients who required surgical bypass were not in-
cluded in the assisted patency calculations. The calculation
of limb salvage/preservation included all major amputa-
tions (below and above knee), whereas toe amputations
were not included in limb salvage computations. Survival
data were obtained from medical records and the Social
Security Database.
Statistical analysis. Patient demographic and risk fac-
tor data associated with intermediate patency and compar-
isons between the two cohorts were performed using 2
with or without Yates correction, Fisher’s exact, Student’s
t, and Mann-Whitney tests, as appropriate. Actuarial pa-
tency and survival analysis was performed using Kaplan-
Meier life tables with Mantel-Cox log-rank univariate anal-
ysis to identify differences between groups. Relative risk
and confidence intervals were then determined using a
multivariate Cox proportional hazards model for data with
variable follow-up. Variables used in themultivariate model
included age, gender, diabetes mellitus, smoking status,
hypertension, congestive heart failure (CHF), dialysis, total
occlusion, stent placement, Rutherford classification, and
TASC classification. A P  .05 was considered significant
for all statistical analysis.
RESULTS
During the study period, 208 patients underwent
PTA/stent on 238 limbs, of which 128 (54%) were per-
formed on patients with lifestyle-limiting claudication
(Rutherford classification 1 to 3) and 110 (46%) were
performed for CLI, presenting as rest pain or tissue loss, as
shown in Table I. Demographic and clinical factors are
summarized in Table II with expected differences in diabe-
tes mellitus, renal failure, and history of CHF in patients
with CLI vs those with claudication. PTA/stent of the
femoropopliteal segment alone was done in 154 patients
(65%), and 84 (35%) underwent multilevel treatment, with
63 (26%) undergoing concomitant PTA of tibial lesions
Table I. Clinical presentation by patients according to
Rutherford classification of percutaneous transluminal
angioplasty
Rutherford category N (%)
1. Mild claudication 2 (1)
2. Moderate claudication 24 (10)
3. Severe claudication 102 (43)
4. Ischemic rest pain 28 (12)
5. Minor tissue loss 77 (32)
6. Major tissue loss 5 (2)and 21 (9%) had concomitant PTA/stent of iliac lesions.Lesion characteristics and treatment features are summa-
rized in Table III. Angiographic success, defined as the
ability to cross and dilate all significant lesions with 20%
residual stenosis, was achieved in 230 (97%) of 238 limbs.
Complications. No deaths were related to PTA/stent
during the study period. Significant complications occurred
in six patients (3%), including two large groin hematomas/
retroperitoneal bleeds requiring blood transfusion, one
intraprocedural thromboembolus that was successfully
managed with thrombolysis and subsequent angioplasty,
one episode of severe flash pulmonary edema requiring
intubation and a short intensive care unit stay, a superficial
femoral artery rupture with expanding thigh hematoma
ultimately requiring a femoropopliteal bypass graft, and
one device malfunction in which the distal segment of a
stent deployment system separated from the catheter and
occluded the superficial femoral artery, leading to a bypass
graft.
Minor systemic events included two patients with wors-
ening CHF that improved with diuresis; two patients with
Table II. Demographic and clinical data
Total
(%)
Claudication
(%) CLI (%) P
Patients 238 128 (54) 110 (46)
Demographics
Male gender 149 (63) 82 (64) 67 (61) .62
Average age (years) 72 72 72 .23
Risk factors
Hypertension 222 (93) 118 (92) 104 (95) .47
Heart disease 141 (59) 72 (56) 69 (63) .31
Diabetes 115 (48) 40 (31) 75 (68) .001
Renal
insufficiency* 68 (29) 25 (20) 43 (39) .002
Dialysis 22 (9) 5 (4) 17 (15) .002
Current smoker 32 (13) 18 (14) 14 (13) .76
Previous smoker 163 (68) 91 (71) 72 (65) .35
Hyperlipidemia 163 (68) 89 (70) 74 (67) .71
CHF 44 (18) 15 (12) 29 (23) .004
CLI, Critical limb ischemia–Rutherford classification 4-6; CHF, congestive
heart failure.
*Renal insufficiency defined as creatinine level of 1.5 mg/dL.
Table III. Anatomic and treatment features
Total
(N  238)
(%)
Claudication
(n  128)
(%)
CLI
(n  110)
(%) P
TASC classification
TASC A 26 (11) 20 (16) 6 (5) .01
TASC B 102 (43) 54 (42) 48 (44) .82
TASC C 98 (41) 48 (37) 50 (46) .21
TASC D 12 (5) 6 (5) 6 (5) .79
Angiographic
findings
Total occlusion 91 (38) 41 (32) 50 (46) .03
Stent placed 53 (22) 34 (27) 19 (17) .11
TASC, Trans Atlantic Inter-Society Consensus.postoperative chest pain, one of whom underwent cardiac
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patients with transient contrast-induced nephropathy. Four
minor groin hematomas were evaluated with duplex ultra-
sound imaging to rule out pseudoaneurysm and were man-
aged with observation.
Finally, 14 patients were noted to have persistent,
flow-limiting arterial dissections that did not respond to
repeat balloon inflations. These were managed with self-
expanding stents. No procedural complications were noted
in the patients who underwent repeat PTA/stent after
primary failure. All patients who underwent PTA/stent for
claudication were discharged home; however, 44 (40%) of
110 with critical limb ischemia were discharged to a reha-
bilitation or skilled nursing facility.
Follow-up. Mean follow-up was 24 months (range,
12 to 42 months). The actuarial cumulative primary pa-
tency (sustained clinical/hemodynamic result without fem-
oropopliteal reintervention) was 64.3% and 54.3% at 24
and 36 months, with a significant difference between those
with claudication (65.6  5.7) and patients with CLI
(42.4  9.9, P  .004 at 36 months; Fig 1). Variables
associated with failure to achieve primary patency by uni-
variate analysis included CHF (P  .002), dialysis (P 
.05), CLI (P  .002), TASC C/D lesions (P  .003), and
an occlusion of any length (P  .005) (Table V, online
only), but only CHF and TASC C/D lesions were signifi-
Fig 1. Kaplan-Meier curves for primary patency of patients un-
dergoing percutaneous transluminal angioplasty stratified by pre-
sentation. S.E., Standard error.cant on multivariate analysis (Table IV).The assisted patency (maintained by redo PTA/stent)
was 92.8%  2.6% at 24 and 36 months, with clinical
presentation having no effect (claudication, 92.7% 3.7%;
CLI, 93.8%  2.7%; P  .31; Fig 2). Factors predictive of
failure to maintain assisted patency by univariate analysis
included age 65 years (P  .031), current smoker (P 
.05), and CHF (P .02) (Table V, online only). Multivar-
Table IV. Significant factors by multivariate analysis
HR 95% CI P
Predictors of primary patency failure
CHF 1.973 1.107-3.525 .02
TASC C/D 1.959 1.099-3.494 .02
Predictors of assisted patency failure
Age 65years 8.325 1.212-57.194 .03
CHF 7.325 1.035-51.854 .008
TASC C/D 7.834 1.696-36.180 .04
Predictors of limb loss
Diabetes 11.481 1.329-99.158 .03
CHF 6.686 1.454-30.745 .02
Predictors of need for eventual surgical bypass
Female gender 4.337 1.437-13.092 .009
CHF 3.648 1.157-11.504 .03
Total occlusion 6.269 1.706-23.038 .006
HR, Hazard ratio; CI, confidence interval; CHF, congestive heart failure;
TASC, Trans Atlantic Inter-Society Consensus.
Fig 2. Kaplan-Meier curves for assisted patency of patients under-
going percutaneous transluminal angioplasty stratified by presen-
tation. S.E., Standard error.iate analysis showed that age 65 and CHF remained
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came significant (Table IV).
Failures of primary patency occurred in 69 (29%) of the
238 in the study population. Of these, 39 (35%) occurred
in the CLI group (n  110), of which 22 (56%) were
managed with repeat PTA, 10 (26%) underwent bypass
grafting, 4 (10%) required amputation for infection or
gangrene, and 3 (8%) were managed conservatively. Four
of the 22 repeat PTAs in the CLI group failed and required
surgical bypass; one of those eventually required amputa-
tion, and the remaining 18 remain open. There were 30
(23%) failures in the claudication group (n  128), 15
(50%) of which were managed with repeat PTA/stent. In
four of these 15 patients, restenosis later occurred in the
femoropopliteal segment, and one was treated with surgical
bypass. The remaining 11 patients remain open. Of the
remaining 15 failures in the claudication patients, five un-
derwent bypass grafting and 10 were observed. Multivari-
ate predictors of need for surgical bypass included female
gender, CHF, and lesion occlusion (Table IV).
The overall limb preservation rate was 95.5%  1.5 at
24 and 36 months, with no amputations occurring in the
claudication group (claudication, 100%  0.0%; CLI,
89.8%  3.3%, P  .0007) (Fig 3). Significant predictors of
limb loss included diabetes (P .009) andCHF (P .003)
by both univariate (Table V, online only) and multivariate
analysis (Table IV). Survival at 36 months was 78.2% 
Fig 3. Kaplan-Meier curves for limb salvage of patients undergo-
ing percutaneous transluminal angioplasty stratified by presenta-
tion. S.E., Standard error.3.1%, with claudication patients faring significantly betterthan those with CLI (93.6% 2.2% vs 60.1% 5.7%, P
.0001; Fig 4).
DISCUSSION
Although the use of PTA/stent as a first line therapy for
chronic lower extremity ischemia was been widely accepted
by cardiologists and interventional radiologists,14,17,20
many series in the vascular surgery literature still recom-
mend surgical bypass as first-line therapy for chronic lower
extremity ischemia, reserving PTA/stent for high-risk pa-
tients and those without autogenous conduit.12,13,21 Re-
cently, Kudo et al11 published a surgical series with 10-year
follow-up, concluding that PTA/stent should be the pri-
mary choice of treatment for CLI. This sentiment was also
reflected in our early results over a more contemporary time
interval.16 Despite these reports, the utility of PTA/stent
remains the topic of an intense debate among surgeons,
which centers around the acceptance of an inferior primary
patency rate of PTA/stent compared with bypass surgery
because of the established substantial reduction in morbid-
ity associated with PTA/stent.16
One issue that has fueled the controversy surrounding
the decision to use PTA/stent over surgical bypass involves
the standards for reporting interval patency and the subse-
quent impact this has on determining therapeutic success.
Primary patency of surgical bypass is dependent on strict
criteria as described by Rutherford’s reporting standards,18
Fig 4. Kaplan Meier curves for survival of patients undergoing
percutaneous transluminal angioplasty stratified by presentation.
S.E., Standard error.and indeed, the added morbidity, hospitalizations, and
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face of a failed graft supports the notion that secondary
patency of infrainguinal bypass is achieved at a high cost to
the patient.
Conversely, although a small number (8%) of patients
in this series eventually required surgical bypass, clinical and
hemodynamic success was maintained inmost patients with
repeat PTA/stent. Given that an acceptable clinical result
can be maintained with a continued low patient morbidity,
it may be more appropriate to forgo the stringent confines
of the primary patency definition of success in favor of
maintained clinical success such as assisted patency. In this
case, the traditional definition of assisted patency has been
modified so that it includes all patients whose clinical
outcome was maintained with percutaneous therapy only,
and those who required surgical bypass or no further inter-
vention were considered failures of percutaneous therapy.
The clinical advantages of PTA/stent have been well
established in high-risk patients. However, can its effective-
ness and associated low morbidity be beneficial enough to
consider it as first-line therapy for all patients presenting
with chronic lower extremity ischemia? In this series, there
was no periprocedural mortality and the rate of major
morbidity was 3%, which is a dramatic improvement over
the recently reported rate of 10% morbidity and 3% mor-
tality after infrainguinal bypass with autogenous vein.22
In addition, all patients with claudication were dis-
charged home after PTA/stent, whereas upwards of 40%
required inpatient rehabilitation or admission to a skilled
nursing facility after bypass surgery regardless of the Ruth-
erford classification upon presentation. Although there is
little argument that morbidity and mortality after PTA/
stent is much lower, the question of the efficacy and dura-
bility of PTA/stent remains the major impediment to its
general acceptance.
Our current result of 97% angiographic success is sim-
ilar to other published series, and the 3-year primary pa-
tency of 54% is in the upper range compared with other
series of femoropopliteal PTA/stent (range, 27% to
60%).11,15,21 More importantly, the primary assisted pa-
tency at 36 months was 92.8%, which is substantially better
than the 24% to 72.5% in previous reports.11,15,21 This
assisted patency was achieved only with repeat percutane-
ous interventions, whereas patency achieved with surgical
bypass was classified as secondary patency (not reported
here for clarity). Finally, no additional morbidity appears to
be associated with repeat PTA/stent procedures, thus con-
tinued limb salvage/symptom relief can bemaintained with
minimal postprocedure disability.
In evaluating PTA/stent, it is important to consider the
mix of patients with claudication and CLI being studied, as
the later has been associated with poorer outcomes after
both surgical bypass and PTA/stent.5,15,22,23 The current
study included 110 limbs (46%) with CLI, whereas the
remaining 128 (54%) had claudication. The primary pa-
tency in patients with claudication was significantly better
than in those with CLI (65.6% vs 42.4%), but the assisted
patency between the two groups did not differ. Indeed, bymultivariate analysis, CLI was not found to be a negative
predictor of primary or secondary patency, and these pa-
tients had a significantly higher long-term mortality, sug-
gesting that PTA/stent is likely the best first option in this
patient cohort.
In addition, almost 20% of primary failures underwent
successful surgical bypass, and in no patient was the option
of surgical bypass eliminated because of PTA/stent. These
data agree with Molloy et al14 and Hynes et al,24 who
concluded that first-line therapy with PTA/stent does not
preclude secondary surgical revascularization for limb sal-
vage in patients with CLI and, in turn, does not lead to
amputations in claudication patients.
The benefit of routine stent placement after balloon
angioplasty has been clearly demonstrated in specific ana-
tomic locations such as in the percutaneous treatment of
lesions in the renal artery orifice. There is, however, debate
regarding this practice in the femoropopliteal segment, and
no randomized trials have demonstrated a benefit of rou-
tinely using a stent over angioplasty alone.25-26 Thus, in
these cases, stents have not been used as the primary
therapy but were reserved in a fail-safe role for patients in
whom angioplasty failed to produce an adequate result or
led to a persistent, flow-limiting dissection. Stents were
placed in 53 limbs (22%), and there was no difference in
primary patency, assisted patency, or limb salvage between
angioplasty alone and angioplasty supplemented with a
stent. This study was not designed to address differences
between devices, and further studies will be necessary to
settle the PTA vs primary stenting issue.
Although clinical presentation (claudication vs CLI) is
a commonly used variable to evaluate PTA/stent out-
come,3,5-6,11-14,17 multivariate analysis of this patient co-
hort indicates that lesion complexity, as determined by the
TASC classification, may be a more reliable predictor of
patency. Surowiec et al15 found that TASC C and D lesions
were associated with a higher incidence of failed or oc-
cluded PTA/stent and recommended that these lesions be
treated with bypass instead of PTA/stent. This sentiment
was mirrored by Cheng et al27 and Kudo et al,11 who
concluded that bypass was the procedure of choice for
TASC D lesions. In contrast, results from the prospectively
collected multicenter Society of Cardiovascular and Inter-
ventional Radiology Transluminal Angioplasty and Revas-
cularisation Registry (STAR) failed to differentiate between
TASC B and C lesions with regards to patency outcomes.28
In the current series with contemporary follow-up,
TASC C and D lesions were significant predicators of
failure of both primary and assisted patency but were not
predictive of limb loss. Despite this finding, the assisted
patency for TASC C/D lesions was 89.7%, with a limb
salvage of 94.2% at 36 months, suggesting that although
reintervention is frequently necessary, acceptable outcomes
can be achieved for even the most advanced lesions. This
finding supports the strong consideration of PTA/stent as
initial interventional therapy in all patients with significant
femoropopliteal occlusive disease.
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tency after PTA/stent include hypertension, diabetes mel-
litus, and renal failure.6,7 None of these affected patency
rates in our series. Interestingly, a history of CHF was a
significant negative predictor of both primary and assisted
patency. Although CHF has been cited as a predictor of
mortality after PTA/stent of vein grafts,28 this is, to our
knowledge, the first report of its association with inferior
patency. This finding is difficult to explain, but it may be
related to a low flow state secondary to impaired cardiac
perfusion or a generalized lack of activity in these patients.
No patient with claudication who underwent PTA/
stent required an amputation, and the limb salvage rate for
patients with CLI was 89.8% at 36 months. Nine amputa-
tions were performed during the study period, all in pa-
tients with TASC B/C lesions and multilevel disease. It
should be pointed out that four amputations were per-
formed for extensive soft tissue necrosis in the face of a
patent femoropopliteal segment and adequate revascular-
ization. Of the remaining five amputations, two patients
had technical failures, one of these patients underwent
surgical bypass that eventually failed, and the other had no
distal target vessel. It is unlikely that these patients could
have avoided amputation if surgical bypass had been the
initial treatment, because eight of the nine had no accept-
able distal target.
Finally, a history of diabetes mellitus was a significant
predictor of amputation on multivariate analysis, as eight of
the nine patients were diabetic. This reflects the disease
state of the patients with tissue loss and poor runoff result-
ing in the associated limb loss. Despite these failures, PTA/
stent remains a viable option even for diabetic patients with
advanced vascular disease and CLI, as 41 such patients in
this study fit these criteria and did not require amputation.
The major limiting factor of this study remains its
retrospective nature, and continued prospective analysis of
PTA/stenting as first-line therapy for chronic lower ex-
tremity ischemia is necessary. In addition, all patients were
treated at a single institution, which opens the potential for
referral/selection bias based on the current practices of the
group. Finally, although the follow-up on primary patency has
reached an intermediate level with a mean of 24 months, that
of assisted patency remains short, and inevitably, this value
would fall with continued surveillance. However, the high
mortality rate in this patient population over the 3-year
study period suggests that many patients will likely be
managed solely with percutaneous interventions as they
succumb to other comorbidities.
CONCLUSION
PTA/stent of the femoropopliteal artery can be per-
formed safely, with a low perioperative morbidity and mor-
tality. Although intermediate primary patency rates remain
low, excellent assisted patency and limb salvage can be
achieved with close follow-up and additional PTA/stent as
necessary. PTA/stent should be considered as initial ther-
apy for patients with both claudication and CLI because
treatment does not preclude reintervention or future sur-gical bypass. Patients with CHF or TASCC/D lesions have
a significantly lower primary and assisted patency, but the
excellent limb salvage achieved in these patients justifies the
use of PTA/stent as first-line therapy in all patients present-
ing with chronic lower extremity ischemia.23,29
AUTHOR CONTRIBUTIONS
Conception and design: MFC, RPC, GML
Analysis and interpretation: MFC, GML
Data collection: MFC, DHS
Writing the article: MFC, DHS, GML
Critical revision of the article: MFC, RPC, DCB, CJK,
MTW, GML
Final approval of the article: MFC, RPC, DHS, DCB, CJK,
MTW, GML, TKC
Statistical analysis: MFC, GML, TKC
Obtained funding: RPC, GML
Overall responsibility: MFC, GML
REFERENCES
1. Hunik MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J,
Harrington DP. Revascularization for femoropopliteal disease: a deci-
sion and cost-effectiveness analysis. JAMA 1995;274:165-71.
2. Yeager RA, Moneta GL, Taylor LM Jr, Hamre DW, McConnell DB,
Porter JM. Surgical management of severe acute lower extremity isch-
emia. J Vasc Surg 1992;15:385-93.
3. Nasr MK, McCarthy RJ, Budd JS, Horrocks M. Infrainguinal bypass
graft patency and limb salvage rates in critical limb ischemia: influence of
mode of presentation. Ann Vasc Surg 2003;17:1992-7.
4. Faries PL, LoGerfo FW, Arora S, Hook S, Pulling MC, Akbari CM,
et al. A comparative study of alternative conduits for lower extremity
revascularization: all-autogenous conduit versus prosthetic grafts. J
Vasc Surg 2000;32:1080-90.
5. Zannetti S, L’Italien GJ, Cambria RP. Functional outcome after surgi-
cal treatment for intermittent claudication. J Vasc Surg 1996;24:65-73.
6. Jamsen TS, Manninen HI, Tulla HE, Jaakkola PA, Matsi PJ. Infrain-
guinal revascularization because of claudication: total long-term
outcome of endovascular and surgical treatment. J Vasc Surg 2003;
37:808-15.
7. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after
infrainguinal bypass surgery: traditional reporting standards systemati-
cally underestimate the expenditure of effort required to attain limb
salvage. J Vasc Surg 2004;39:330-5.
8. Schepers A, Klinkert P, Peeters V, Breslau PJ. Complication registration
in patients after peripheral arterial bypass surgery. Ann Vasc Surg
2003;17:198-202.
9. L’Italien GJ, Cambria RP, Cutler BS, Leppo JA, Paul SD, Brewster DC,
et al. Comparative early and late cardiac morbidity among patients
requiring different vascular surgery procedures. J Vasc Surg 1995;21:
935-44.
10. Gibbons G, Burgess AM, Guadagnoli E, Pomposelli FB, Freeman DV,
Campbell DR, et al. Return to well-being and function after infraingui-
nal revascularization. J Vasc Surg 1995;21:35-45.
11. Kudo T, Fiona AC, Ahn SS. The effectiveness of percutaneous translu-
minal angioplasty for the treatment of critical limb ischemia: a 10-year
experience. J Vasc Surg 2005;41:423-35.
12. Parsons RE, Suggs WD, Lee JJ, Sanchez LA, Lyon RT, Veith FJ.
Percutaneous transluminal angioplasty for the treatment of limb threat-
ening ischemia: do the results justify an attempt before bypass grafting?
J Vasc Surg 1998;28:1066-71.
13. London NJ, Varty K, Sayers RD, Thompson MM, Bell PR, Bolia A.
Percutaneous transluminal angioplasty for lower-limb critical ischemia.
Br J Surgery 1995;82:1232-5.
14. Molloy KJ, Nasim A, London NJ, Bell PR, Fishwick GB, Thomposn
MM. Percutaneous transluminal angioplasty in the treatment of critical
limb ischemia. J Endovasc Ther 2003;10:298-303.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Conrad et al 76915. Surowiec SM, Davies MG, Eberly SW, Rhodes JM, Illig KA, Shortell
CK, et al. Percutaneous angioplasty and stenting of the superficial
femoral artery. J Vasc Surg 2005;41:269-78.
16. Black JH, LaMuraglia GM, Kwolek CJ, Brewster DC, Watkins MT,
Cambria RP. Contemporary results of angioplasty-based infrainguinal
percutaneous interventions. J Vasc Surg 2005;42:932-9.
17. Nasr MK, McCarthy RJ, Hardman J, Chalmers A, Horrocks M. The
increasing role of percutaneous transluminal angioplasty in the primary
management of critical limb ischemia. Eur J Vasc Endovasc Surg
2002;23:398-403.
18. Rutherford FB, Baker JD, Ernst C, Johnston KW, Porter JM, Anh S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
19. Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD). TASC working group. Trans Atlantic Inter-Society
Consensus (TASC). J Vasc Surg 2000;31:S1-296.
20. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Bross-
mann J. Endovascular placement of self-expanding Nitinol coil stents
for the treatment of femoropopliteal obstructive disease. J Vasc Interv
Radiol 2002;13:257-66.
21. Lofberg AM, Karacagil S, Ljungman C, Westman B, Bostrom A,
Helberg A, et al. Percutaneous transluminal angioplasty of the femoro-
popliteal arteries in limbs with chronic critical lower limb ischemia. J
Vasc Surg 2001;34:114-21.
22. Abbruzzese TA, Havens J, BelkinM, DonaldsonMC,Whittemore AD,
Liao JK, et al. Statin therapy is associated with improved patency of
autogenous infrainguinal bypass grafts. J Vasc Surg 2004;39:1178-85.
23. Tefera G, Hoch J, Turnipseed WD. Limb-salvage angioplasty in vascu-24. Hynes N, Akhtar Y, Manning B, Aremu M, Oiakhinan K, Courtney D,
Sultan S. Subintimal angioplasty as a primary modality in the manage-
ment of critical limb ischemia: comparison to bypass grafting for aor-
toiliac and femoropopliteal occlusive disease. J Endovasc Ther 2004;11:
460-71.
25. Vroegindewejj D, Vos LD, Tielbeek AV, Buth J, Bosch HC. Balloon
angioplasty combined with primary stenting versus balloon angioplasty
alone in femoropopliteal obstructions: a comparative randomized trial.
Int Angiol 1997;18:251-55.
26. Becqiemim J, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A.
Systematic versus selective stent placement after superficial femoral
artery balloon angioplasty. A multicenter prospective randomized
study. J Vasc Surg 2003;37:487-94.
27. Cheng SWK, Ting ACW, Ho P. Angioplasty and primary stenting of
high-grade, long-segment superficial femoral artery disease: is it worth-
while? Ann Vasc Surg 2003;17:430-7.
28. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency
after femoropopliteal angioplasty: results from the STAR registry. J Vasc
Interv Radiol 2001;12:923-33.
29. Keeley EC, Velez CA, O’Neil WW, Safian RD. Long-term clinical
outcome and predictors of major adverse cardiac events after percuta-
neous interventions on saphenous vein grafts. J Am Coll Cardio 2001;
38:659-65.
Submitted Oct 14, 2005; accepted Jun 25, 2006.
Additional material for this article may be found online
lar surgery practice. J Vasc Surg 2005;41:988-93. at www.jvascsurg.org.
CME Credit Now Available to JVS Readers
Readers can now obtain CME credits by reading selected articles and correctly answering multiple choice
questions on the Journal website (www.jvascsurg.org). Four articles are identified in the Table of
Contents of each issue and 2 questions for each are posted on the website. After correctly answering the
8 questions, readers will be awarded 2 hours of Category I CME credit.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 4 Conrad et al 769.e1Table V (online only). Univariate results of variables used for multivariate analysis
Variable
Primary patency Assisted patency Limb salvage Survival
Coef P Coef P Coef P Coef P
Age 0.61 .06 3.85 .04 0.44 .31 2.12 .02
Gender 0.79 .35 0.78 .71 0.77 .69 1.88 .08
Diabetes 1.33 .24 2.69 .16 9.66 .03 1.87 .04
Smoking 0.72 .41 3.63 .07 0.82 .85 0.86 .74
Hypertension 1.38 .53 1.16 .84 0.64 .58 0.68 .48
CHF 2.23 .003 4.43 .02 5.71 .01 3.66 .001
Dialysis 1.97 .07 — — 1.47 .71 6.05 .001
Occlusion 1.86 .01 0.92 .88 2.29 .3 1.13 .69
Critical limb ischemia 1.97 .006 1.94 .32 — — 6.19 .001
TASC C/D 2.15 .002 1.81 .38 1.46 .58 1.1 .74
CHF, congestive heart failure; TASC, Trans Atlantic Inter-Society Consensus.
